Loading stock data…
$27.99-1.06 (-3.65%)
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases.
Vera Therapeutics, Inc. in the Healthcare sector is trading at $27.99 with a market capitalization of $2.4B. Wall Street consensus targets $74.20 (15 analysts), implying a +165.1% move over the next 12 months. The stock is currently near its 52-week low of $23.05, remaining 25.2% below its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$112.49M↑ | -$125.13M↓ | -$94.21M↓ | -$83.93M↓ | -$80.14M |
| Net Income | -$109.47M↑ | -$121.03M↓ | -$91.10M↓ | -$80.29M↓ | -$76.53M |
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion pr...